Are we over-treating with checkpoint inhibitors?

Anti-PD-1 antibodies offer potentially life-saving treatment for some cancer patients, but their chronic administration generates high and ever-increasing costs. Despite licensing for long-term use, optimal treatment duration is unknown. We challenge the need for long-term treatment duration, using...

Full description

Saved in:
Bibliographic Details
Published in:Br J Cancer
Main Authors: Danson, Sarah, Hook, Jane, Marshall, Helen, Smith, Alexandra, Bell, Sue, Rodwell, Simon, Corrie, Pippa
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2019
Subjects:
Comment
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6889152/
https://ncbi.nlm.nih.gov/pubmed/31527686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0570-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items